These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31853144)

  • 41. Tumour lysis syndrome: new therapeutic strategies and classification.
    Cairo MS; Bishop M
    Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens.
    Weeks AC; Kimple ME
    J Investig Med High Impact Case Rep; 2015; 3(3):2324709615603199. PubMed ID: 26904699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and management of tumor lysis syndrome in adults with malignancy.
    Sarno J
    J Adv Pract Oncol; 2013 Mar; 4(2):101-6. PubMed ID: 25031988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
    Latha SM; Krishnaprasadh D; Murugapriya P; Scott JX
    Indian J Nephrol; 2015; 25(2):91-4. PubMed ID: 25838646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O; Robitaille LM; Cairo MS
    Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spontaneous Tumour Lysis Syndrome in Mantle Cell Lymphoma: A Case Study.
    Taha N; Bhaskar G
    Cureus; 2022 Oct; 14(10):e29851. PubMed ID: 36212272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
    Ngo JS; Ho MHM
    Can J Hosp Pharm; 2019; 72(4):311-319. PubMed ID: 31452543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose rasburicase in hematologic malignancies.
    Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
    Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Incidence and Risk Assessment of Tumor Lysis Syndrome in Patients with Advanced Germ Cell Cancer].
    Kurobe M; Kawai K; Tanaka K; Ichioka D; Yoshino T; Kandori S; Kawahara T; Waku N; Takaoka E; Kojima T; Joraku A; Suetomi T; Miyazaki J; Nishiyama H
    Hinyokika Kiyo; 2016 May; 62(5):237-42. PubMed ID: 27320114
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
    Moss JD; Wu M; Axelrod DM; Kwiatkowski DM
    Cardiol Young; 2019 Sep; 29(9):1160-1164. PubMed ID: 31451121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
    Mughal TI; Ejaz AA; Foringer JR; Coiffier B
    Cancer Treat Rev; 2010 Apr; 36(2):164-76. PubMed ID: 20031331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor Lysis Syndrome in Patients With Hepatocellular Carcinoma: A Systematic Review of Published Case Reports.
    Chou JW; Cheng KS; Akella T; Lee CC; Ju T
    Cureus; 2021 Oct; 13(10):e19128. PubMed ID: 34858764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
    Shukla DK; Gupta D; Aggarwal A; Kumar D
    Indian J Med Paediatr Oncol; 2017; 38(3):360-362. PubMed ID: 29200691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
    Azim HA; Bahr SA; Kamal NS; Koura MA; Tolba R; Gad HA; Morsy A; Attia HM; Iskander I; Hammad A; Hemed MF; Abdallah MF; Sadek KA; Taha AH
    Ecancermedicalscience; 2013; 7():378. PubMed ID: 24324529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.